EUVIMEDEUVIMED entdecken
Open Access

VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma

Yaqing Ding, Qi Zhan, Longtao Cui, Xiaoteng Cui, Yilin Zhao, Qixue Wang, Biao Hong, Yanping Huang, Dongyuan Su, Chunchao Cheng, Hanyi Xu, Siwen Liang und 3 weitere

Neuro-Oncology · 01.04.2026 · 28 (4) · 864-879

DOI: 10.1093/neuonc/noaf293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 31.12.2025. Verfasst von Yaqing Ding und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-Neuro Injury Neuro-…. Hauptthemen laut MEDLINE: Glioblastoma, Bevacizumab, Hypoxia-Inducible Factor 1, alpha Subunit, Temozolomide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, NSFC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is characterized by extensive tissue hypoxia. This hypoxic microenvironment drives chemoresistance and promotes aberrant vascularization, critically limiting the efficacy of temozolomide (TMZ) and bevacizumab (BEV). Here, we report EPIC-0502, a novel small-molecule competitive antagonist that inhibits hypoxia signaling while sensitizing GBM to both TMZ and BEV.

Methods

EPIC-0502 was identified through molecular dynamics simulation. Its target blocking effect was validated via non-targeted metabolomics, stable isotope tracing-based metabolic flux analysis, and pull-down assays. The mechanisms underlying EPIC-0502 activity were elucidated by Western Blot (WB), Co-Immunoprecipitation (Co-IP), ELISA, Seahorse assays, and Immunofluorescence (IF). The sensitizing effects of EPIC-0502 on TMZ and BEV were evaluated in orthotopic GBM models.

Results

EPIC-0502 inhibited α-ketoglutarate (α-KG) to succinate conversion, depleting cytoplasmic succinate levels and inhibiting phosphoglycerate kinase 1 (PGK1) succinylation and phosphorylation, which significantly attenuated glycolysis. Furthermore, EPIC-0502 destabilized Hypoxia-inducible factor 1 alpha (HIF1α) by promoting hydroxylation-dependent ubiquitination, while impairing its transcriptional activity. Through HIF1α degradation, EPIC-0502 enhanced GBM sensitivity to TMZ via E2F1 downregulation and reversed hypoxia-induced vascular endothelial growth factor A (VEGFA) overexpression, potentiating the antiangiogenic efficacy of BEV. Collectively, these actions enable EPIC-0502 to synergistically enhance the therapeutic efficacy of TMZ/BEV combination.

Conclusions

Based on EPIC-0502-driven HIF1α degradation that overcomes BEV resistance and synergizes with TMZ, we propose the novel VITA-GBM regimen comprising: Vascular targeting (BEV), Inhibition of hypoxia signaling (EPIC-0502), TMZ chemotherapy, and Alignment of synergistic mechanisms. This strategy enhances the efficacy of first-line therapies and provides a promising approach to improve overall survival in GBM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBevacizumabHypoxia-Inducible Factor 1, alpha SubunitTemozolomideDrug Resistance, NeoplasmBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceDrug SynergismXenograft Model Antitumor AssaysMice, NudeTumor Cells, Cultured

Stichwörter der Autor:innen

HIF1αTMZ sensitizationbevacizumabglioblastomaprotein succinylation

Substanzen

BevacizumabHypoxia-Inducible Factor 1, alpha SubunitTemozolomideHIF1A protein, human

Autor:innen und Institutionen

  • Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Educati…

ORCID-Profile: Chunsheng Kang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • NSFC

Zitieren

APA

Ding, Y., Zhan, Q., Cui, L., Cui, X., Zhao, Y., Wang, Q., Hong, B., Huang, Y., Su, D., Cheng, C., Xu, H., Liang, S., Zhao, X., Liu, Y., & Kang, C. (2026). VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma. Neuro-Oncology, 28(4), 864-879. https://doi.org/10.1093/neuonc/noaf293

Vancouver

Ding Y, Zhan Q, Cui L, Cui X, Zhao Y, Wang Q, et al. VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma. Neuro-Oncology. 2026;28(4):864-879. doi:10.1093/neuonc/noaf293

BibTeX
@article{Ding2026,
  author = {Ding, Yaqing and Zhan, Qi and Cui, Longtao and Cui, Xiaoteng and Zhao, Yilin and Wang, Qixue and Hong, Biao and Huang, Yanping and Su, Dongyuan and Cheng, Chunchao and Xu, Hanyi and Liang, Siwen and Zhao, Xun and Liu, Yuhao and Kang, Chunsheng},
  title = {VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {4},
  pages = {864--879},
  doi = {10.1093/neuonc/noaf293}
}
Kostenlos starten →